ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that based upon recommendations from an independent Safety Monitoring Committee (SMC) the company is progressing into the next stage of the enrollment of patients in its study of a hepatitis B immunotherapy. In this study, a total of 45 patients with chronic hepatitis B virus (HBV) infection are being randomized within three separate groups to receive immunotherapy or placebo. The immunotherapy utilizes the company’s proprietary spi-VEC delivery system to deliver the hepatitis B core antigen, in order to induce an immune response to the hepatitis B virus.
